Curtis Advisory Group LLC Makes New Investment in Amgen Inc. $AMGN

Key Points

• Curtis Advisory Group purchased a new position of 5,100 shares in Amgen (NASDAQ: AMGN) during Q4, valued at about $1.669 million.
• Amgen beat Q4 estimates with $5.29 EPS (vs. $4.76 expected) and $9.87B revenue, set FY2026 guidance at 21.600–23.000 EPS, and announced a quarterly dividend of $2.52 (annualized $10.08, ~2.9% yield).
• Analysts' consensus is a Hold with an average price target of $355.84, institutional investors own roughly 76.5% of the stock, and recent analyst targets range from about $326 to $410, signaling mixed near-term views.

Curtis Advisory Group LLC purchased a new position in Amgen Inc. (NASDAQ:AMGN - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 5,100 shares of the medical research company's stock, valued at approximately $1,669,000.

A number of other hedge funds have also recently added to or reduced their stakes in AMGN. Board of the Pension Protection Fund acquired a new stake in Amgen in the 4th quarter worth about $26,000. Olistico Wealth LLC acquired a new stake in Amgen in the 4th quarter worth about $33,000. Cloud Capital Management LLC acquired a new stake in Amgen in the 3rd quarter worth about $34,000. Saranac Partners Ltd acquired a new stake in Amgen in the 3rd quarter worth about $37,000. Finally, Holos Integrated Wealth LLC acquired a new stake in Amgen in the 4th quarter worth about $37,000. 76.50% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts have issued reports on the company. Morgan Stanley raised their price target on Amgen from $309.00 to $326.00 and gave the stock an "equal weight" rating in a research note on Friday. TD Cowen reissued a "buy" rating on shares of Amgen in a research note on Wednesday, February 4th. Freedom Capital lowered Amgen from a "strong-buy" rating to a "hold" rating in a research note on Thursday, February 12th. Daiwa Securities Group raised their price target on Amgen from $370.00 to $410.00 and gave the stock an "outperform" rating in a research note on Tuesday, February 10th. Finally, Weiss Ratings reissued a "buy (b)" rating on shares of Amgen in a research note on Monday, December 29th. One analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, thirteen have given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, Amgen currently has an average rating of "Hold" and an average target price of $355.84.

Amgen Stock Performance

Amgen stock opened at $350.92 on Friday. The stock's 50-day moving average is $363.87 and its 200-day moving average is $335.08. The company has a market cap of $189.39 billion, a price-to-earnings ratio of 24.66, a price-to-earnings-growth ratio of 3.48 and a beta of 0.47. The company has a debt-to-equity ratio of 5.78, a current ratio of 1.14 and a quick ratio of 0.90. Amgen Inc. has a 12 month low of $261.43 and a 12 month high of $391.29.

Amgen (NASDAQ:AMGN - Get Free Report) last released its quarterly earnings data on Tuesday, February 3rd. The medical research company reported $5.29 EPS for the quarter, topping analysts' consensus estimates of $4.76 by $0.53. The company had revenue of $9.87 billion for the quarter, compared to the consensus estimate of $9.46 billion. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The company's quarterly revenue was up 8.6% compared to the same quarter last year. During the same period last year, the business posted $5.31 EPS. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Equities analysts anticipate that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 5th. Stockholders of record on Friday, May 15th will be issued a $2.52 dividend. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.9%. The ex-dividend date is Friday, May 15th. Amgen's dividend payout ratio (DPR) is 70.84%.

More Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: China approval for tarlatamab expands Amgen’s lung-cancer market access and supports future revenue in a large oncology market — a meaningful commercial win for a new oncology asset. Amgen's lung cancer drug tarlatamab wins China approval
• Positive Sentiment: Phase‑4 FORWARD II gout study update: a less‑frequent Krystexxa dosing schedule could improve patient adherence and lifetime drug value, which would be positive for product uptake and revenue stability. Amgen’s FORWARD II Gout Study
• Positive Sentiment: Analyst bullishness on fundamentals: Zacks argues Amgen is poised to beat earnings again, supported by its recent history of surprise results and solid guidance — this can underpin near‑term sentiment ahead of the next report. Why Amgen (AMGN) is Poised to Beat Earnings Estimates Again
• Positive Sentiment: Royal Bank of Canada raised its price target to $370, signaling upside from some institutional analysts and suggesting conviction in Amgen’s mid‑term growth drivers. Royal Bank Of Canada Increases Amgen Price Target
• Neutral Sentiment: Guggenheim nudged its target to $351 while retaining a neutral rating — little immediate directional impact given the price is near that level. Amgen Price Target Raised to $351 at Guggenheim
• Neutral Sentiment: Short‑interest data reported for April appears inconsistent/erroneous (reads as 0 shares / NaN increase), so it’s unlikely to be a reliable driver of today’s action. (data entry)
• Neutral Sentiment: Media pieces highlighting Amgen’s profitability and recent TEPEZZA subcutaneous Phase‑3 topline results reinforce the company’s longer‑term value story but are incremental to near‑term price moves. Is Amgen One of the Most Profitable Value Stocks?
• Negative Sentiment: Morgan Stanley’s latest stance (equal‑weight, target raised only to $326) and other hold ratings emphasize limited near‑term upside vs. current levels — that analyst positioning is weighing on the stock. Morgan Stanley equal weight on Amgen

About Amgen

Amgen Inc NASDAQ: AMGN is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.